Lino-Silva Leonardo S, Loaeza-Belmont Reynaldo, Gómez Álvarez Miguel A, Vela-Sarmiento Itzel, Aguilar-Romero José M, Domínguez-Rodríguez Jorge A, Salcedo-Hernández Rosa A, Ruiz-García Erika B, Maldonado-Martínez Héctor A, Herrera-Gómez Ángel
Department of Gastrointestinal Pathology, Instituto Nacional de Cancerología, Mexico City, Mexico.
Department of Gastrointestinal Pathology, Instituto Nacional de Cancerología, Mexico City, Mexico.
Clin Colorectal Cancer. 2017 Mar;16(1):73-77. doi: 10.1016/j.clcc.2016.05.001. Epub 2016 Jun 8.
Most cases of rectal cancer (RC) in our institution are in pathologic stage T3. They are a heterogeneous group but have been classified in a single-stage category. We performed the present study to validate the prognostic significance of the mesorectal extension depth (MED) in T3 RC measured in millimeters beyond the muscularis propria plane.
We performed a retrospective analysis of 104 patients with T3 RC who had undergone curative surgery after a course of preoperative chemoradiotherapy at a tertiary referral cancer hospital. The patients were grouped by MED (T3a, < 1 mm; T3b, 1-5 mm; T3c > 5-10 mm; and T3d > 10 mm). The clinicopathologic data and disease-free survival were analyzed.
The 5-year disease-free survival rate according to the T3 subclassification was 87.5% for those with T3a, 57.9% for T3b, 38.7% for T3c, and 40.3% for those with T3d tumors (P = .050). On univariate and multivariate analysis, the prognostic factors affecting survival were overall recurrence (hazard ratio [HR], 3.670; 95% confidence interval [CI], 1.710-7.837; P = .001), histologic grade (HR, 2.204; 95% CI, 1.156-4.199; P = .016), mesorectal invasion depth (HR, 1.885; 95% CI, 1.164-3.052; P = .010), and lymph node metastasis (HR, 1.211; 95% CI, 1.015-1.444; P = .033).
MED is a significant prognostic factor in patients with T3 RC who have undergone neoadjuvant chemoradiotherapy, especially when the MED is > 5 mm. The MED could be as important as other clinicopathologic factors in predicting disease-specific survival.
在我们机构中,大多数直肠癌(RC)病例处于病理T3期。它们是一个异质性群体,但被归为单一阶段类别。我们开展本研究以验证在固有肌层平面以外以毫米为单位测量的直肠系膜浸润深度(MED)在T3期直肠癌中的预后意义。
我们对一家三级转诊癌症医院中104例接受了术前化疗放疗后进行根治性手术的T3期直肠癌患者进行了回顾性分析。患者按MED分组(T3a,<1毫米;T3b,1 - 5毫米;T3c,>5 - 10毫米;T3d,>10毫米)。分析临床病理数据和无病生存期。
根据T3亚分类,T3a患者的5年无病生存率为87.5%,T3b为57.9%,T3c为38.7%,T3d肿瘤患者为40.3%(P = 0.050)。单因素和多因素分析显示,影响生存的预后因素包括总体复发(风险比[HR],3.670;95%置信区间[CI],1.710 - 7.837;P = 0.001)、组织学分级(HR,2.204;95% CI,1.156 - 4.199;P = 0.016)、直肠系膜浸润深度(HR,1.885;95% CI,1.164 - 3.052;P = 0.010)和淋巴结转移(HR,1.211;95% CI,1.015 - 1.444;P = 0.033)。
MED是接受新辅助化疗放疗的T3期直肠癌患者的重要预后因素,尤其是当MED>5毫米时。在预测疾病特异性生存方面,MED可能与其他临床病理因素同样重要。